SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-106144
Filing Date
2021-04-05
Accepted
2021-04-05 14:25:32
Documents
12
Period of Report
2021-04-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d111003d8k.htm   iXBRL 8-K 21924
  Complete submission text file 0001193125-21-106144.txt   144060

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cbay-20210401.xsd EX-101.SCH 3065
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20210401_lab.xml EX-101.LAB 18137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20210401_pre.xml EX-101.PRE 11404
5 EXTRACTED XBRL INSTANCE DOCUMENT d111003d8k_htm.xml XML 3359
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 21804855
SIC: 2834 Pharmaceutical Preparations